California Insulin Program Remains Over a Year Away to Market

The rollout of California’s program to develop low-cost copycat versions of insulin, known as biosimilars, remains more than a year away from distribution, a top official told state lawmakers Wednesday.

Vishaal Pegany, deputy director for the state’s Office of Health Care Affordability, said clinical trials will begin soon for drugs under the delay-plagued program, but could not offer certainty when the drugs may reach the market to help the more than 3 million Californians with diabetes.

Gov. Gavin Newsom (D) previously said the state would begin to deliver the drugs in 2024 as part of its CalRx program, which aims ...